ConvaTec buys shares as ConvaTec stock sits 11.07 percent below its 52-week high

Published on 10/13/2026 at 06:19 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

ConvaTec bought 1,328,340 shares through October 2, 2026. ConvaTec stock was GBp 230.60 on October 12, 2026, below GBp 259.30.

ConvaTec repurchased 1,328,340 shares through October 2, 2026, under its up to USD 200 million buyback program.
The company held 133,813,259 shares in treasury after the purchases, with 1,915,976,300 ordinary shares in issue.
ConvaTec stock was last quoted at GBp 230.60 on October 12, 2026, 11.07 percent below its GBp 259.30 52-week high.
Barclays maintained a Buy rating with a GBp 300.00 price target on October 1, 2026.

Geometrisches Bauhaus-Poster mit Sektor-Schriftzug MEDTECH in kräftigen Farben — ConvaTec Group Plc GB00BD3VFW73 inspiriert geometrisches Bauhaus-Poster mit Sektor-Schriftzug MEDTECH in kräftigen Grundfarben, Illustration mit AI erstellt.

ConvaTec Group Plc (ISIN GB00BD3VFW73) bought 1,328,340 shares between September 28 and October 2, 2026, as part of its up to USD 200 million buyback program, while ConvaTec stock stood 11.07 percent below its 52-week high of GBp 259.30. The transaction was published by Investegate on October 5, 2026.

What does the buyback change?

Following the purchases, ConvaTec held 133,813,259 shares in treasury and had 1,915,976,300 ordinary shares in issue. The buyback therefore reduced the shares available outside treasury while leaving the issued-share figure clearly defined for voting-right calculations, according to Investegate.

Three dated company developments

On August 6, 2026, ConvaTec announced an interim dividend of 2.166 cents per share for the six months ended June 30, 2026, a 15.4 percent increase from 1.877 cents, according to Simply Wall St. On August 30, 2026, the company appointed Dr Jens Viebke as a non-executive director, bringing more than 30 years of healthcare technology experience, the same source reported. The October 5 buyback update was the latest of the three dated developments.

Results show growth and pressure

For the first half of 2026, ConvaTec reported USD 1.23 billion of revenue, up 4.40 percent from the first half of 2025, while net income fell 49.00 percent to USD 54.00 million. The figures show continued sales expansion alongside a sharp earnings decline, according to Markets Insider.

Barclays maintained a Buy rating for ConvaTec on October 1, 2026, with a GBp 300.00 price target. That target is 30.13 percent above the GBp 230.60 quote, based on the target and the latest LSE price, while the analyst view contrasts with the first-half net income decline.

Upcoming reporting dates

ConvaTec is scheduled to provide a trading update on November 18, 2026, according to MarketBeat. The company is also scheduled to report fiscal year 2026 results on February 23, 2027, according to Simply Wall St.

Stock remains below its yearly high

ConvaTec was last quoted at GBp 230.60 on the LSE on October 12, 2026 at 6:16 p.m. London time. The 52-week range was GBp 193.00 to GBp 259.30, placing the quote 11.07 percent below the high. The further course of trading is shown by the continuously updated real-time quote of ConvaTec stock.